How To Be Picky About Job Offers - Even In Economic Downtimes https://t.co/wO7AQpvPCw https://t.co/wO7AQpvPCw ...

Company Overview - Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a biopharmaceutical company that employs a modality-agnostic approach to drug development, targeting biological mechanisms in oncology and autoimmune conditions [1] Business Strategy - The company selects the most effective modality for each therapeutic target, indicating a flexible strategy that adapts to various treatment needs [1] Partnerships - Cullinan Therapeutics engages in partnerships to enhance its drug development capabilities, which may provide additional resources and expertise [1]

Core Viewpoint - Akeso, Inc. has initiated a Phase III clinical trial for ivonescimab as a first-line treatment for advanced metastatic colorectal cancer (mCRC), addressing a significant unmet clinical need in this area [1][2][7]. Industry Overview - Colorectal cancer is the third most common cancer globally and the second leading cause of cancer-related deaths, with over 1.9 million new cases and approximately 904,000 deaths reported in 2022 [3]. - About 95% of mCRC cases are classified as microsatellite stable (MSS) or proficient mismatch repair (pMMR), which traditionally show poor responses to immunotherapy [3]. - Current standard treatments for mCRC include chemotherapy combined with targeted therapies, but the overall efficacy remains limited, with a five-year survival rate for advanced patients of less than 20% [4]. Company Initiatives - The Phase III trial (AK112-312/HARMONi-GI6) aims to validate the clinical benefits of ivonescimab, which has shown promising Phase II efficacy data in combination with chemotherapy for MSS/pMMR-type mCRC [5][7]. - The combination of ivonescimab with FOLFOXIRI demonstrated an overall response rate (ORR) of 81.8% and a disease control rate (DCR) of 100%, indicating compelling anti-tumor activity in this difficult-to-treat patient population [6]. Future Prospects - If successful, ivonescimab could provide a novel first-line immunotherapy treatment option for patients with advanced mCRC, potentially improving outcomes compared to existing therapies [7].

The impact of President Trump’s whirlwind six months back in office is beginning to show up in the economy https://t.co/8ihDyY5BuM ...

Core Insights - Jin Medical International Ltd. has launched production at its new intelligent manufacturing facility in Chuzhou, Anhui, China, aiming to enhance its rehabilitation medical equipment supply chain [1][2] - The facility is equipped to produce 200,000 units annually, adhering to Japanese Industrial Standards (JIS) for quality [2] - Jin Medical's product range includes ultra-light wheelchairs, competition-grade equipment, micro hyperbaric oxygen chambers, and beauty devices, reflecting a commitment to meet diverse health needs [3] Company Overview - Founded in 2006, Jin Medical is headquartered in Changzhou, Jiangsu Province, China, and specializes in designing, developing, and manufacturing products for rehabilitation and elderly care [6] - The company operates two existing manufacturing plants totaling approximately 230,000 square feet and is establishing a new facility of 430,000 square feet in Chuzhou [6] - Jin Medical collaborates with over 40 distributors in China and more than 20 international distributors, primarily selling its wheelchair products in Japan and China [6] Strategic Vision - The CEO of Jin Medical emphasized a shift in rehabilitation technology towards enhancing quality of life, leveraging intelligent manufacturing to meet global health demands [4] - The company is actively testing new electric wheelchairs for distribution in senior care communities and rehabilitation centers across various international locations [4] - Jin Medical aims to bridge the gap between East and West in rehabilitation technology, positioning itself for future growth on the global stage [5]

M Morgan Stanley Research: Key Forecasts July 14, 2025 09:35 PM GMT Extel Survey: If you've found our research useful, we'd appreciate your support for the Morgan Stanley Cross-Asset Strategy team and our colleagues in the 2025 Extel Global Fixed Income Survey, especially in USA/EMEA/Asia Cross-Asset Strategy categories. Next 12 Months Outlook: Our High-Conviction Calls Skewed to the Downside: In the US, the labor market is holding up, but cooling gradually. Although the recent US inflation data did not sho ...

The new Vera C. Rubin Observatory has already detected interstellar object 3I/ATLAS and may detect up to 50 more during its 10-year mission, according to a new model. (Photo: Javier Torres/AFP via Getty Images)https://t.co/vywd7iTLhM https://t.co/vf53aA3NOk ...

Core Viewpoint - Euro Manganese Inc. has announced the appointment of Sherry Roberge as Interim Chief Financial Officer and Martina Blahova to the Board of Directors, effective July 15, 2025, which is expected to enhance the company's strategic execution in the battery materials sector [1][3]. Company Appointments - Sherry Roberge, a Chartered Professional Accountant with over 15 years of experience in the resource sector, has been appointed as Interim Chief Financial Officer. Her background includes roles at NorthX Nickel Corp. and Defiance Silver Corp., focusing on corporate governance, regulatory compliance, and financial reporting [2][3]. - Martina Blahova, currently the President and CEO, has also been appointed to the Board of Directors, following her successful acquisition of a Director Identification Number from the Australian Business Registry Services [3]. Company Overview - Euro Manganese is focused on producing high-purity manganese for the electric vehicle industry, with ongoing development of the Chvaletice Manganese Project in the Czech Republic and an early-stage opportunity in Bécancour, Québec [4][5]. - The Chvaletice Project involves reprocessing old tailings from a decommissioned mine, positioning the company as a key supplier of critical raw materials for battery supply chains in the European Union [5].

How India's Mumbai is spending billions to get rid of extreme traffic and messy roads to compete with global finance hubs like Hong Kong and Singapore. https://t.co/JrJLzCzrFV ...

NEW YORK, July 15, 2025 /PRNewswire/ -- Fly-E Group, Inc. (Nasdaq: FLYE) ("Fly-E" or the "Company"), an electric vehicle company engaged in designing, installing, selling, and renting smart electric motorcycles, electric bikes, and electric scooters, today announced its financial results for the fiscal year ended March 31, 2025.Fiscal Year 2025 Financial Summary Net revenues were $25.4 million in fiscal year 2025, compared to $32.2 million in fiscal year 2024. Gross profit was $10.5 million in fiscal year 2 ...